Showing results (611-620 of 667) with videos related to

Sort By:
Pageof 67
Cancer Immunology, Immunotherapy : CII|January 18, 2024
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatmentJoanna Baginska, Allison Nau, Ilana Gomez Diaz, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
Cancer|June 23, 2020
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitisShilpa Grover, Michael Dougan, Kevin Tyan, et al.
Cancer Immunology Research|April 11, 2025
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Metastatic Melanoma PatientsF Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Cancer Immunology Research|January 31, 2015
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanomaRachel Lubong Sabado, Anna Pavlick, Sacha Gnjatic, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2022
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.
Pageof 67